{"filing":{"accession_number":"0001193125-26-329520","cik":"0001625297","ticker":"INDV","company_name":"Indivior Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"d118566d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/d118566d8k.htm"},"events":[{"id":23006,"run_id":20826,"accession_number":"0001193125-26-329520","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Indivior issued a press release on August 3, 2026 reporting Q2 2026 financial results for the period ended June 30, 2026, with total net revenue of $343 million (up 14% YoY), record SUBLOCADE net revenue of $253 million (up 21% YoY), record GAAP net income of $122 million, and record adjusted EBITDA of $186 million (up 111% YoY), along with raised full-year 2026 guidance.","company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23141,"accession_number":"0001193125-26-329520","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Indivior issued a press release on August 3, 2026 reporting Q2 2026 financial results for the period ended June 30, 2026, disclosing total net revenue of $343 million (up 14% YoY), record SUBLOCADE net revenue of $253 million (up 21% YoY), record GAAP net income of $122 million, and record adjusted EBITDA of $186 million (up 111% YoY). The company also raised full-year 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:50:42.272407+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23142,"accession_number":"0001193125-26-329520","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Indivior's Q2 2026 financial results, including total net revenue of $343 million (up 14% YoY), record SUBLOCADE net revenue of $253 million (up 21% YoY), record GAAP net income of $122 million, and record adjusted EBITDA of $186 million (up 111% YoY). The company also raised its full-year 2026 guidance. This is a standard earnings release presentation posted on the company's website and furnished as Exhibit 99.2, disclosing quarterly and year-to-date financial results with forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:50:42.272407+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23141,"accession_number":"0001193125-26-329520","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Indivior issued a press release on August 3, 2026 reporting Q2 2026 financial results for the period ended June 30, 2026, disclosing total net revenue of $343 million (up 14% YoY), record SUBLOCADE net revenue of $253 million (up 21% YoY), record GAAP net income of $122 million, and record adjusted EBITDA of $186 million (up 111% YoY). The company also raised full-year 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:50:42.272407+00:00","company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","filing_date":"2026-08-03"},{"id":23142,"accession_number":"0001193125-26-329520","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Indivior's Q2 2026 financial results, including total net revenue of $343 million (up 14% YoY), record SUBLOCADE net revenue of $253 million (up 21% YoY), record GAAP net income of $122 million, and record adjusted EBITDA of $186 million (up 111% YoY). The company also raised its full-year 2026 guidance. This is a standard earnings release presentation posted on the company's website and furnished as Exhibit 99.2, disclosing quarterly and year-to-date financial results with forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T10:50:42.272407+00:00","company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","filing_date":"2026-08-03"}]}